| abstract |
The present invention provides a boric acid compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and use thereof as an active ingredient in preparing an NLRP3 inflammasome inhibitor. The compounds can selectively inhibit the activation of the NLRP3 inflammasome, so that the diseases related to the NLRP3 inflammasome, such as colitis, can be treated or ameliorated, and thus can be used to prepare a therapeutic drug for the diseases related to the NLRP3 inflammasome. |